New hope for elderly myeloma patients: talquetamab trial opens

NCT ID NCT06827860

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tests a drug called talquetamab in elderly patients whose multiple myeloma has come back after earlier treatments. The drug is given as a shot under the skin and aims to help the body's immune cells attack the cancer. If the drug stops working, another drug called daratumumab may be added. The goal is to see if this approach is safe and effective for patients who are not candidates for more aggressive therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.